Enanta Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that its CEO, Jay R. Luly, Ph.D., will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 4:40 p.m. ET. Investors can access a live webcast on Enanta's website under the "Events and Presentations" section, with a replay available for 30 days post-event. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with clinical candidates targeting RSV, SARS-CoV-2, and HBV. The company is funded by royalties from its HCV collaboration with AbbVie.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will give a corporate presentation at the Oppenheimer 32^nd Annual Healthcare Conference on Tuesday, March 15, 2022, at 4:40 p.m. ET.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the event and will be archived for 30 days.

About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005212/en/

Media and Investor

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta's CEO present at the Oppenheimer Conference?

Enanta's CEO, Jay R. Luly, will present on March 15, 2022, at 4:40 p.m. ET.

Where can I watch the Enanta Pharmaceuticals conference presentation?

The presentation can be viewed live on Enanta's website in the "Events and Presentations" section.

How long will the Enanta conference presentation be available for replay?

The replay of the conference presentation will be available for 30 days after the event.

What diseases is Enanta Pharmaceuticals targeting?

Enanta is targeting respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and hepatitis B virus (HBV) with its drug development.

What is the funding source for Enanta's research and development?

Enanta's R&D activities are primarily funded through royalties from its hepatitis C virus products developed in collaboration with AbbVie.